Encouraging outcome from these studies supported clinical efficacy of EGFR for anti-cancer therapy and led to the development of EGFR-targeting antibodies like cetuximab or panitumumab and TKIs like gefitinib, erlotinib, and lapatinib. The gene discussed is EGFR; the disease is cancer.